| 000 | 01400 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250513063929.0 | ||
| 264 | 0 | _c19940616 | |
| 008 | 199406s 0 0 eng d | ||
| 022 | _a0091-6749 | ||
| 024 | 7 |
_a10.1016/0091-6749(94)90380-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCugno, M | |
| 245 | 0 | 0 |
_aActivation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid. _h[electronic resource] |
| 260 |
_bThe Journal of allergy and clinical immunology _cMay 1994 |
||
| 300 |
_a870-6 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAcute Disease |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAngioedema _xblood |
| 650 | 0 | 4 |
_aAutoantibodies _xblood |
| 650 | 0 | 4 |
_aAutoimmune Diseases _xblood |
| 650 | 0 | 4 |
_aComplement C1 Inactivator Proteins _xdeficiency |
| 650 | 0 | 4 |
_aComplement System Proteins _xanalysis |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFibrinolysis _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aTranexamic Acid _xadministration & dosage |
| 700 | 1 | _aCicardi, M | |
| 700 | 1 | _aAgostoni, A | |
| 773 | 0 |
_tThe Journal of allergy and clinical immunology _gvol. 93 _gno. 5 _gp. 870-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0091-6749(94)90380-8 _zAvailable from publisher's website |
| 999 |
_c8181547 _d8181547 |
||